include "/home/remark/public_html/header_clinical.php"; ?>
Zhang, et al., China Medical Abstracts (1994), 3114 conducted a double-blind, placebo-controlled study of 62 patients whose diagnosis met the DSM-III-R and CCMD-2 criteria for obsessive-compulsive disorder. These patients were randomly assigned to three treatment groups: 22 were treated with chlorimipramine, 20 with phenytoin and 20 with placebo. Before and after a 4-week treatment period, the Y-BOCS, MSCPOR, and HAMD rating scales were administered, and the clinical effects were also evaluated.
The data revealed the percentage of full recovery and marked improvement in the chlorimipramine and phenytoin groups was 68% and 55% respectively. There was no improvement in the patients receiving placebo. The mean reduction in the Y-BOCS and MSCPOR rating scales of patients receiving chlorimipramine, phenytoin and placebo at the end of 4-week treatment was 54.69%, 46.05%, 6.94% and 18.88%, 22.13%, 3.2% respectively. The authors conclude that their results suggest that both chlorimipramine and phenytoin were effective in the treatment of obsessive-compulsive disorder.
3114. Zhang, Y., et al., The study of phenytoin in the treatment of obsessive-compulsive disorder with double-blind, placebo-controlled trial, China Med. Abstr. ,11(2):68, 1994.
However, the limited information available on this topic has indicated that PHT is not useful in the treatment of anger and related emotions: impatience, irritability resentment, aggrivation and rage.See also: Gilles de la Tourette Syndrome
Advisoryinclude "/home/remark/public_html/footer.php"; ?>